Compound research
TB-500 Peptide: Product Identity, COAs, and Lot-Specific Research Documentation

TB-500 is a synthetic research peptide associated with thymosin beta-4 fragment research. In an evidence-first catalogue review, the compound name is only the starting point. The specific product, labeled strength, and lot or sample identifier determine which analytical record can be used to evaluate the material.
Review the individual product listing first. Confirm the product name, labeled quantity, product format, and current documentation status. A report for another strength, lot, or similarly named material may be useful background, but it does not document the exact item under review.
Read the stated analytical method alongside the reported result. Relative purity, molecular identity, measured content, and endotoxin status are separate analytical questions. A single result should not be treated as proof of every product attribute unless the report identifies both the applicable method and the named sample.
The key fields on a TB-500 COA are the sample identity, lot or sample identifier, issuing laboratory, analysis date, method, and result. Those fields establish what material was assessed and the limited scope of the document. The lot or sample identifier is especially important because it prevents a generic certificate from being treated as batch-specific evidence.
Standalone TB-500 items and multi-analyte blends that include TB-500 must be reviewed separately. A blend has a distinct product identity and needs a report that identifies the blended material. A standalone TB-500 result does not verify a blend, and a blend record does not replace a standalone TB-500 record.
EVLV supplies TB-500 strictly for lawful laboratory and analytical research. This guide covers product identity and documentation review only. It does not provide dosing, administration, medical, veterinary, or outcome guidance.

